What is the current market valuation of the US alpha thalassemia market?

The market valuation was $1020.19 Million in 2024. Read More

What is the projected market size for the US alpha thalassemia market by 2035?

The projected market size is $2957.64 Million by 2035. Read More

What is the expected CAGR for the US alpha thalassemia market during the forecast period 2025 - 2035?

The expected CAGR is 10.16% during the forecast period 2025 - 2035. Read More

Which companies are the key players in the US alpha thalassemia market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Pfizer, Roche, GSK, Sanofi, Celgene, and Vertex Pharmaceuticals. Read More

What are the main segments of the US alpha thalassemia market?

Main segments include Type, Diagnosis, Treatment, and End-User. Read More

What was the market value for Hb Bart syndrome in 2024?

The market value for Hb Bart syndrome was $150.0 Million in 2024. Read More

What is the projected market value for HbH disease by 2035?

The projected market value for HbH disease is $850.0 Million by 2035. Read More

How much is the perinatal testing segment valued at in 2024?

The perinatal testing segment was valued at $1020.19 Million in 2024. Read More

What is the projected value of gene therapy in the treatment segment by 2035?

The projected value of gene therapy in the treatment segment is $657.64 Million by 2035. Read More

What is the market value for hospitals as an end-user in 2024?

The market value for hospitals as an end-user was $204.06 Million in 2024. Read More

US Alpha Thalassemia Market

ID: MRFR/LS/17741-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Alpha Thalassemia Market Research Report By Type (hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome, HbH disease, silent carrier state, trait), By Diagnosis (perinatal testing, prenatal testing, pre-implantation, complete blood count (CBC), DNA testing, prenatal genetic testing, chorionic villus sampling), By Treatment (blood transfusions, iron chelation, bone marrow or stem cell transplant, surgery, gene therapy) and By End-User (hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries, others) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Hb Bart syndrome
  2. 4.1.2 HbH disease
  3. 4.1.3 silent carrier state
  4. 4.1.4 trait
2. 4.2 Construction, BY Diagnosis (USD Million)
  1. 4.2.1 perinatal testing
  2. 4.2.2 prenatal testing
  3. 4.2.3 pre-implantation
3. 4.3 Construction, BY Treatment (USD Million)
  1. 4.3.1 blood transfusions
  2. 4.3.2 iron chelation
  3. 4.3.3 bone marrow or stem cell transplant
  4. 4.3.4 surgery
  5. 4.3.5 gene therapy
4. 4.4 Construction, BY End-User (USD Million)
  1. 4.4.1 hospitals
  2. 4.4.2 biotechnological laboratories
  3. 4.4.3 diagnostic laboratories
  4. 4.4.4 educational research institutes
  5. 4.4.5 pharmaceutical industries
  6. 4.4.6 others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GSK (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Celgene (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Vertex Pharmaceuticals (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END-USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

Hb Bart syndrome
HbH disease
silent carrier state
trait

Construction By Diagnosis (USD Million, 2025-2035)

perinatal testing
prenatal testing
pre-implantation

Construction By Treatment (USD Million, 2025-2035)

blood transfusions
iron chelation
bone marrow or stem cell transplant
surgery
gene therapy

Construction By End-User (USD Million, 2025-2035)

hospitals
biotechnological laboratories
diagnostic laboratories
educational research institutes
pharmaceutical industries
others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”